Zelira Therapeutics (ASX:ZLD) raises A$1.77M from US-based investors

Zelira Therapeutics (ASX:ZLD) has announced a successful direct capital raise of A$1.77M from US-based investors to provide additional working capital for further progressing its strategies and FDA clinical trials.

Zelira Therapeutics is a global biopharmaceutical company that researches, develops and commercialises clinically validated cannabinoid-based medicines.

The company says it owns a portfolio of proprietary revenue-generating products, as well as a pipeline of candidates undergoing clinical development.

Zelira Therapeutics also says it generates revenue from two proprietary medications, HOPE® and ZENIVOL®.